Cortexin
clinical trialsAlso known as: Cortexin polypeptide complex
**Mechanism of Action** Cortexin is a low-molecular-weight polypeptide complex extracted from bovine cerebral cortex. It is proposed to exert neuroprotective and nootropic effects through multiple mechanisms, including modulation of GABAergic and glutamatergic neurotransmission, reduction of oxidative stress, and enhancement of cerebral energy metabolism. The peptide complex is thought to cross the blood-brain barrier and promote neuronal repair by upregulating neurotrophic factors (e.g., BDNF) and inhibiting pathological apoptosis. Its polyvalent action also includes anti-inflammatory effects via suppression of microglial activation and normalization of neurotransmitter imbalances. **Key Research Findings** Clinical trials, primarily conducted in Eastern Europe, have demonstrated Cortexin’s efficacy in improving cognitive function, reducing neurological deficits, and accelerating recovery in conditions such as traumatic brain injury, chronic cerebral ischemia, and encephalopathy. A 2019 meta-analysis of randomized controlled trials reported significant improvements in Mini-Mental State Examination (MMSE) scores and neurological symptom scales compared to placebo. Preclinical studies further indicate that Cortexin reduces infarct volume in stroke models and enhances synaptic plasticity in aged rodents. However, most trials have small sample sizes and lack rigorous blinding, limiting generalizability. **Clinical Relevance** Cortexin is approved in Russia and several CIS countries for the treatment of cognitive disorders, cerebrovascular pathology, and developmental delays in children. Its clinical use is supported by evidence of short-term cognitive benefits and safety, with rare adverse effects (e.g., mild allergic reactions). Despite promising data, the lack of large-scale, multinational trials and standardized dosing protocols restricts its acceptance in Western medicine. Further research is needed to validate its efficacy across diverse populations and to elucidate its precise molecular targets. For research purposes only — not medical advice.
Key data
Research & studies
MoCA scores improved from 25.1 to 28.4 points after two Cortexin courses, with gains in attention, short-term memory, and executive functions.; Cognitive improvements were maintained at delayed testing (28.0 points).; Quality of life (SF-36) significantly improved after the fourth visit and continued positive trend at the fifth visit.; Cortexin was effective, safe, and well tolerated in young post-stroke patients.
Cerebrolysin probably results in little to no difference in all-cause death (RR 0.96, 95% CI 0.65 to 1.41; moderate-certainty evidence).; Cerebrolysin probably results in little to no difference in total serious adverse events (RR 1.16, 95% CI 0.81 to 1.66; moderate-certainty evidence).; Cerebrolysin may increase non-fatal serious adverse events (RR 2.39, 95% CI 1.10 to 5.23; moderate-certainty evidence), especially with a 30 mL for 10 days regimen (RR 2.87, 95% CI 1.24 to 6.69).; Evidence on non-death attrition and adverse events was low or very low certainty, showing no clear difference.
Social cognition is examined as a separate cognitive function essential for normal mental development.; The theory of mind and its neurobiological foundations are discussed.; Social competence impairments are reported in autism, specific language impairment, ADHD, and specific learning disorder.; Key neurocognitive deficits in social cognition and possibilities for pharmacological correction are reviewed.
High glucose (50 mM) caused a significant decrease in mean area under the curve (AUC) compared to normoglycemic conditions.; Cortexin co-treatment attenuated the high glucose-induced effect in a concentration-dependent manner.; At 40 μg/mL, Cortexin significantly increased AUC from 0.18 to 0.66 versus high glucose alone.; Cortexin alone increased AUC values in normoglycemic conditions in a concentration-dependent manner.
Frequently asked questions
What is Cortexin?
**Mechanism of Action** Cortexin is a low-molecular-weight polypeptide complex extracted from bovine cerebral cortex. It is proposed to exert neuroprotective and nootropic effects through multiple mechanisms, including modulation of GABAergic and glutamatergic neurotransmission, reduction of oxidative stress, and enhan
How does Cortexin work?
Bovine cortex-derived polypeptide complex used clinically in Eastern Europe for encephalopathy and cognitive disorders.
What is the research status of Cortexin?
Cortexin is currently classified as clinical trials, with 201 research references on record. This is for research purposes only and is not medical advice.
Related peptides
CNTF-derived peptidergic compound that promotes neurogenesis and reduces tau pathology in preclinical Alzheimer's models.
33-aa hypothalamic neuropeptide acting on OX1/OX2 receptors to promote wakefulness and arousal.
Porcine brain-derived peptide preparation with neurotrophic-factor-like activity studied in stroke, TBI, and dementia.
Ligand for NPSR1 . Binds to its receptor with nanomolar affinity and initiates a G /GNAQ-dependent phospholipase C-activating signaling pathway. This results in Ca mobilization from intracellular stores and increased int…
NCAM-derived FG-loop peptide that activates FGFR1 to enhance synaptic plasticity and memory in animal models.
May function as an output molecule from the suprachiasmatic nucleus that transmits behavioral circadian rhythm.
Build on Cortexin data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key